Marinus Pharmaceuticals Ownership
| MRNS Stock | USD 1.30 0.08 5.80% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 56.7 M | Current Value 56.9 M | Avarage Shares Outstanding 19.3 M | Quarterly Volatility 18.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Marinus |
Marinus Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.64. Marinus Pharmaceuticals last dividend was issued on the 23rd of September 2020. The entity had 1:4 split on the 23rd of September 2020. Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. Marinus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people. To find out more about Marinus Pharmaceuticals contact Scott MD at 484 801 4670 or learn more at https://marinuspharma.com.Besides selling stocks to institutional investors, Marinus Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Marinus Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Marinus Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Marinus Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Marinus Pharmaceuticals are currently held by insiders. Unlike Marinus Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Marinus Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Marinus Pharmaceuticals' insider trades
Marinus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Marinus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Marinus Pharmaceuticals backward and forwards among themselves. Marinus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Marinus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sofinnova Ventures | 2023-12-31 | 1.8 M | Gmt Capital Corp | 2023-12-31 | 1.7 M | Bain Capital Life Sciences Investors, Llc | 2023-12-31 | 1.4 M | Geode Capital Management, Llc | 2023-12-31 | 1.1 M | State Street Corporation | 2023-12-31 | 1 M | Woodline Partners Lp | 2023-12-31 | 800 K | Ikarian Capital, Llc | 2023-12-31 | 746.1 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 583.8 K | Opaleye Management Inc | 2023-12-31 | 563.5 K | Suvretta Capital Management, Llc | 2023-12-31 | 5.3 M | Blackrock Inc | 2023-12-31 | 4.6 M |
Marinus Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Marinus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Marinus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Marinus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pair Trading with Marinus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marinus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marinus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Marinus Stock
| 0.78 | ACB | Aurora Cannabis Financial Report 12th of June 2024 | PairCorr |
| 0.74 | HCM | HUTCHMED DRC Earnings Call This Week | PairCorr |
| 0.68 | CGC | Canopy Growth Corp Earnings Call This Week | PairCorr |
| 0.53 | MRK | Merck Company Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Marinus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marinus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marinus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marinus Pharmaceuticals to buy it.
The correlation of Marinus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marinus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marinus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Marinus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marinus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Marinus Stock analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Marinus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marinus Pharmaceuticals. If investors know Marinus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marinus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 0.514 | Quarterly Revenue Growth (0.26) | Return On Assets (0.46) | Return On Equity (4.23) |
The market value of Marinus Pharmaceuticals is measured differently than its book value, which is the value of Marinus that is recorded on the company's balance sheet. Investors also form their own opinion of Marinus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Marinus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marinus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Marinus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marinus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marinus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marinus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.